title: Enhanced Chemotherapeutic Behavior of Open-Caged DNA@Doxorubicin Nanostructures for Cancer Cells.
abstract: In cancer therapy, it is imperative to increase the efficacy and reduce side effects of chemotherapeutic drugs. Nanotechnology offers the unique opportunity to overcome these barriers. In particular, in the last few years, DNA nanostructures have gained attention for their biocompatibility, easy customized synthesis and ability to deliver drugs to cancer cells. Here, an open-caged pyramidal DNA@Doxorubicin (Py-Doxo) nanostructure was constructed with 10 DNA sequences of 26-28 nucleotides for drug delivery to cancer cells. The synthesized DNA nanostructures are sufficiently stable in biological medium. Py-Doxo exhibited significantly enhanced cytotoxicity of the delivered doxorubicin to breast and liver cancer cells up to twofold compared to free doxorubicin. This study demonstrates the importance of the shape and structure of the designed transporter DNA nanostructures for biomedical applications.
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.
authors.forename: Vinit
authors.initials: V
authors.lastname: Kumar
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.|Doctoral School in Nanotechnology, University of Trieste, Italy.
authors.forename: Samer
authors.initials: S
authors.lastname: Bayda
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.|Doctoral School in Pharmacological Sciences, University of Padua, Italy.
authors.forename: Mohamad
authors.initials: M
authors.lastname: Hadla
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.
authors.forename: Isabella
authors.initials: I
authors.lastname: Caligiuri
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.
authors.forename: Concetta
authors.initials: C
authors.lastname: Russo Spena
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.|Doctoral School in Nanotechnology, University of Trieste, Italy.
authors.forename: Stefano
authors.initials: S
authors.lastname: Palazzolo
authors.affiliation: Faculty of Physics and Center for Nanoscience, Ludwig-Maximilians-Universität München, München, Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Kempter
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Corona
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Toffoli
authors.affiliation: Clinical Pharmacology, Department of Molecular Biology and Translational Research, National Cancer Institute and Center for Molecular Biomedicine, PN, Italy.
authors.forename: Flavio
authors.initials: F
authors.lastname: Rizzolio
mesh_terms: D001943:Breast Neoplasms / Q000188:drug therapy* / Q000235:genetics; D045744:Cell Line, Tumor; D018736:DNA Adducts / Q000627:therapeutic use*; D004317:Doxorubicin / Q000627:therapeutic use*; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D006801:Humans; D049329:Nanostructures
chemical_list: D018736:DNA Adducts; C031902:doxorubicin-DNA; D004317:Doxorubicin